iBio Inc. (IBIO)
NASDAQ: IBIO
· Real-Time Price · USD
0.82
0.02 (2.92%)
At close: Sep 26, 2025, 1:00 PM
iBio Revenue Breakdown
| Period Ending | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ibio Cdmo Revenue | 143K | 168K | 127K | 491K | 65K | 515K | 203K | -1K | 21K | 72K | 161K | n/a | 527K | 651K | 45K | 78K | 153K | 84K | 110K |
| Ibio Cdmo Revenue Growth | -14.88% | +32.28% | -74.13% | +655.38% | -87.38% | +153.69% | -20400.00% | -104.76% | -70.83% | -55.28% | n/a | -100.00% | -19.05% | +1346.67% | -42.31% | -49.02% | +82.14% | -23.64% | n/a |
| Ibio Inc Revenue | 1.8M | n/a | 84K | 1K | 700K | 190K | 207K | 1.12M | 75K | 242K | 108K | 795K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Ibio Inc Revenue Growth | n/a | -100.00% | +8300.00% | -99.86% | +268.42% | -8.21% | -81.53% | +1394.67% | -69.01% | +124.07% | -86.42% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.97M | 2.74M | 2.8M | 2.44M | 2.72M | 2.96M | 3.55M | 2.61M | 3.52M | 7.79M | 5.09M | 10.61M | 5.32M | 5.37M | 4.17M | 6.65M | 5.31M | 5.81M | 5.57M | 3.7M | 3.16M | 2.58M | 2.99M | 3.22M | 2.84M | 3.39M | 2.87M | 3M | 2.6M | 2.59M | 2.5M | 2.89M | 2.84M | 2.35M | 2.47M | 2.18M | 2.4M | 1.68M | 1.42M | 1.45M | 1.22M |
| Selling, General, and Administrative Revenue Growth | +8.42% | -2.11% | +14.61% | -10.21% | -8.07% | -16.52% | +35.95% | -25.99% | -54.77% | +53.18% | -52.03% | +99.51% | -1.04% | +28.67% | -37.18% | +25.09% | -8.49% | +4.20% | +50.59% | +17.05% | +22.47% | -13.56% | -7.38% | +13.36% | -16.18% | +18.18% | -4.14% | +14.97% | +0.70% | +3.56% | -13.68% | +2.01% | +20.67% | -4.78% | +13.47% | -9.45% | +42.70% | +18.42% | -1.80% | +18.49% | n/a |
| Research and Development Revenue | 1.91M | 1.88M | 1.3M | 1.14M | 904K | 1.53M | 1.61M | 2.36M | 2.64M | 2.78M | 2.55M | 6.34M | 3.27M | 1.86M | 2.51M | 3.1M | 2.16M | 2.44M | 1.76M | 349K | 999K | 888K | 977K | 1.62M | 1.45M | 1.27M | 1.12M | 1.04M | 966K | 993K | 985K | 1.11M | 1.14M | 1.05M | 820K | 853K | 1.05M | 704K | 551K | 764K | 815K |
| Research and Development Revenue Growth | +1.55% | +43.83% | +14.47% | +26.11% | -41.11% | -4.42% | -31.83% | -10.89% | -4.86% | +9.07% | -59.79% | +93.64% | +76.01% | -25.97% | -18.92% | +43.25% | -11.54% | +38.71% | +404.87% | -65.07% | +12.50% | -9.11% | -39.84% | +11.77% | +14.14% | +13.26% | +7.87% | +7.87% | -2.72% | +0.81% | -11.42% | -2.11% | +8.29% | +27.93% | -3.87% | -18.61% | +48.86% | +27.77% | -27.88% | -6.26% | n/a |